Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $73.0452W HIGH $129.65
Volume
2.98 M
Value Traded
385.69 M
Short % Float
5.02%
Days to Cover
1.0
-0.02%Week
+1.03%1 Month
+57.57%3 Month
+22.28%6 Month
+65.21%5 Year
+453.25%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
8.37 B
EPS (TTM)
-2.46
P/E Ratio
-
Ent. Value
8.51 B
Total Shares
64.67 M
Float Shares
62.35 M
Insiders
3.71%
Institutions
106.61%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
BPMC Catalyst Timeline
Dated clinical, regulatory and corporate events for Blueprint Medicines Corporation
Past FDA Catalysts and PDUFA Decisions
How BPMC actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2023-05-22 | Ayvakit (avapritinib) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
3
Drugs Scored
rNPV / MCap
Top Drug
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BLU-808 Small moleculeNCT06931405 | Chronic Inducible Urticaria | Phase 2 | ACTIVE NOT_RECRUITING | 105 | Dec 31, 2026 | ||||||
| Elenestinib Small moleculeNCT04910685 | Indolent Systemic Mastocytosis | Phase 2/3 | RECRUITING | 534 | Sep 30, 2032 | ||||||
| Avapritinib Small moleculeMarketedNCT03731260 | Indolent Systemic Mastocytosis | Approved | ACTIVE NOT_RECRUITING | 251 | Jun 23, 2027 | ||||||
| Avapritinib Small moleculeMarketedNCT06327685 | Systemic Mastocytosis With an Associated Hematologic Neoplasm | Approved | RECRUITING | 34 | Mar 1, 2027 | ||||||
| BLU-808 Small moleculeCompletedNCT06922448 | Allergic Rhinoconjunctivitis | Phase 2 | COMPLETED | 21 | Sep 8, 2025 | ||||||
| Fisogatinib Small moleculeCompletedNCT02508467 | Hepatocellular Carcinoma (HCC) | Phase 1 | COMPLETED | 146 | Feb 28, 2024 | ||||||
| Avapritinib Small moleculeMarketedNCT03465722 | GIST | Approved | COMPLETED | 476 | Sep 15, 2021 | ||||||
| Avapritinib Small moleculeMarketedNCT03580655 | Advanced Systemic Mastocytosis | Approved | COMPLETED | 107 | Dec 18, 2024 | ||||||
| Avapritinib Small moleculeMarketedNCT02561988 | Aggressive Systemic Mastocytosis | Approved | COMPLETED | 86 | Jan 19, 2023 | ||||||
| Avapritinib Small moleculeNot countedNCT04773782 | Solid Tumor, Unspecified, Child | Phase 1/2 | COMPLETED | 29 | Nov 21, 2025 | ||||||
| Avapritinib Small moleculeMarketedNCT04908176 | Gastrointestinal Stromal Tumors | Approved | COMPLETED | 260 | May 10, 2024 |
Clinical Trial Results
Readouts, endpoints and source filings for every BPMC program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| AYVAKIT | systemic mastocytosis | 2025-06-12 | follow-up reaching up to five years in ISM; up to 6.5 years in advanced SM; sustained disease control in ISM; prolonged survival in advanced SMRead More | Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI CongressesRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Rossi ChristinaOfficer (CHIEF OPERATING OFFICER) | Sell | -1,172 63,546 held | $128.25 | 07/03/2025 |
Hedge Fund 13F Activity
Hedge Funds invested in BPMC
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Avoro Capital Advisors LLC | 0.8 % (-84.9 %) | 48.07 M | 375.00 K | -90.26% ( -3.48 M) |
Ownership Trends
BPMC Short Interest
Shares sold short, counted twice a month.
5.02%
Short % of Float
of tradable shares sold short
1.7M
Shares Sold Short
-54.7% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
3.5M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BPMC ranks across every disease it competes in
Competitive Position is a premium feature
See how BPMC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBPMC News
About Blueprint Medicines Corporation
BIOPHARMAWATCH ELITE PLUS
Trade the next BPMC catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime